Quell Therapeutics and Cellistic™ enter a strategic collaboration

After Ncardia launched its affiliate company Cellistic last week, dedicated to making large-scale allogeneic cell therapy production a reality, they are proud to now enter a strategic collaboration with Quell Therapeutics, to develop an iPSC-derived allogeneic T-regulatory cell therapy platform.

London, UK and Gosselies, Belgium – April 27 2022 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, and Cellistic™, the iPSC-focused cell therapy process development & manufacturing partner recently launched by Ncardia to make large-scale allogeneic cell therapy production a reality, announce they have entered into a strategic collaboration for the co-development of an iPSC-derived Treg cell therapy platform. The goal of the partnership is to facilitate the future expansion of Quell’s autologous Treg cell therapy pipeline by adding off-the-shelf, allogeneic Treg cell therapy products, leveraging Cellistic™’s expertise in differentiation and scale-up of iPSC processes for allogeneic cell therapy applications.

Iain McGill, Chief Executive Officer, Quell Therapeutics, said:

“Quell has made significant progress advancing the first candidate from our autologous multi-modular Treg cell therapy platform into the clinic, with the initiation of our LIBERATE study of QEL-001 to prevent liver transplant rejection. We believe there is significant opportunity to transform outcomes for patients with QEL-001 and other autologous Treg cell therapy products in our pipeline. Our collaboration with Cellistic™ is a key building block in our investment towards a future, next-generation allogeneic Treg cell platform, which could significantly expand our opportunities to develop novel off-the-shelf treatments across a wide range of diseases driven by immune dysregulation. We highly respect the expertise and experience of Ncardia and the Cellistic™ team, and its track record in developing rapidly scalable iPSC cell therapy processes.”


Read the full press release here!

Source: Ncardia

Logo Cellistic

‹ News overview